Pneumococcal Vaccines Archive
-- Superseded Infrormation -- HISTORICAL USE ONLY -- See Current Information --New Information Resource Regarding Pneumococcal Vaccine Use in Children
June 03, 2010 -- The Bureau of Immunization would like to direct your attention to a particularly timely and useful document developed by the Immunization Action Coalition (IAC).
This document, directed towards a healthcare provider audience, is a concise "one-pager" presenting recommendations, schedules, and answers to questions concerning pneumococcal vaccine use in children.
This document was promoted in a recent IAC Express (#870) as follows:
Many healthcare providers have questions about the use of the new 13-valent pneumococcal conjugate vaccine (PCV13), especially when dealing with catch-up vaccination and children with medical conditions that are indications for both PCV and pneumococcal polysaccharide vaccine (PPSV23). To help answer such questions, the IAC has developed a new handout, Recommendations for Pneumococcal Vaccine Use in Children, that spells out the recommendations for every scenario.
This new resource includes three tables. The first table provides the recommended PCV13 schedule based on the child's age and PCV7 and/or PCV13 vaccination history. The second table provides the recommended schedule for administering PPSV23 vaccine to children. The third table lists the underlying medical conditions that are indications for pneumococcal vaccination among children.
The IAC's Handouts for Patients and Staff web section offers healthcare professionals and the public approximately 250 FREE English-language handouts (many also available in translation), which we encourage website users to print out, copy, and distribute widely.
- To access all of IAC's free handouts, go to www.immunize.org/handouts
- A pdf of the document is available at www.immunize.org/catg.d/p2016.pdf
Vaccine Information Statement News
The Bureau of Immunization is pleased to highlight the recent publication of the 13-valent pneumococcal conjugate vaccine (PCV13). Details can be found at www.cdc.gov/vaccines/pubs/vis/vis-news.htm. It may be used immediately, and is preferred over the previous PCV VIS. The new VIS is located at www.cdc.gov/vaccines/pubs/vis/default.htm#pcv.
Many VIS are available in Spanish and other languages at www.immunize.org/vis.
Healthcare providers should periodically access the VIS electronically and print out a supply for routine distribution. If necessary, bureau staff can FAX copies to providers without internet access. Please contact my staff.
Links to the latest vaccine information statements can be found at:
- Centers for Disease Control and Prevention
- Immunization Action Coalition (primary source for translated VIS)
ACIP Recommendations for Pneumococcal Conjugate and Meningococcal Vaccines
March 18, 2010 -- The Bureau of Immunization is pleased to bring to your attention two important articles published by the Centers for Disease Control and Prevention (CDC) on March 12, 2010, in the Morbidity and Mortality Weekly Report (MMWR Weekly / Vol. 59 / No. 9). These two articles, Licensure of a 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Recommendations for Use Among Children -- Advisory Committee on Immunization Practices (ACIP), 2010 (page 258) and Licensure of a Meningococcal Conjugate Vaccine (Menveo®) and Guidance for Use -- Advisory Committee on Immunization Practices (ACIP), 2010 (page 273), describe the recommendations and use of two important vaccines in the healthcare provider's disease prevention plan.
Please be sure to check for published updates and errata.
We encourage providers to read these recommendations and guidance carefully, since we include only excerpts here.
Licensure of a 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Recommendations for Use Among Children -- Advisory Committee on Immunization Practices (ACIP), 2010
On February 24, 2010, a 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13™, Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.]) was licensed by the Food and Drug Administration (FDA) for prevention of invasive pneumococcal disease (IPD) caused by the 13 pneumococcal serotypes covered by the vaccine and for prevention of otitis media caused by serotypes in the 7-valent pneumococcal conjugate vaccine formulation (PCV7 [Prevnar®, Wyeth]). PCV13 is approved for use among children 6 weeks to 71 months of age and succeeds PCV7, which was licensed by FDA in 2000. The Pneumococcal Vaccines Work Group of the ACIP reviewed available data on the immunogenicity, safety, and cost-effectiveness of PCV13, and on estimates of the vaccine-preventable pneumococcal disease burden. The working group then presented policy options for consideration of the full ACIP.
This report summarizes recommendations approved by ACIP on February 24, 2010, for:
- Routine vaccination of all children 2 through 59 months of age with PCV13.
- Vaccination with PCV13 of children 60 through 71 months of age with underlying medical conditions that increase their risk for pneumococcal disease or complications.
- PCV13 vaccination of children who previously received 1 or more doses of PCV7.
The CDC's guidance for vaccination providers regarding transition from PCV7 to the PCV13 immunization program also is included.
PCV13 is available for ordering through the Vaccines for Children (VFC) Program on March 18, 2010. The VFC Program will provide program specific ordering information.
Providers should return unused Prevnar® 7 remaining in their offices, after the receipt of Prevnar 13™, as quickly as possible. Each provider office will receive return labels from McKesson Customer Service for return of unused doses of Prevnar® 7. Once the provider office receives a shipment of Prevnar 13™, the remaining Prevnar® 7 doses should be boxed and returned to McKesson. These doses do not need to be shipped as viable vaccine. Only public-purchased doses should be returned to McKesson. Please direct any questions regarding ordering and returning of Prevnar® products to the VFC Program staff at (800) 483-2543.
Updated Pneumococcal Conjugate Vaccine Information Statement
December 11, 2008 -- The Centers for Disease Control and Prevention (CDC) published a new interim Vaccine Information Statement (VIS) for Pneumococcal Conjugate Vaccine (PCV). It incorporates recent updates in recommendations for healthy children 2 through 4 years of age, as well as miscellaneous minor changes. The previous VIS may still be used until stocks are depleted.
By Federal law, all vaccine providers must give patients, their parents, and/or legal representatives the appropriate VIS whenever a vaccination is given. As needed, providers should supplement VIS forms orally, with videotapes, with additional printed material, or in any other way that will help recipients understand the disease and vaccine. Sufficient time should be allotted to review the VIS and discuss:
- Benefits of the vaccines
- Diseases they prevent
- Any contraindications or possible known risks from the vaccines
- What to expect following the immunization
A contact number should be provided to the parent or guardian in the event there are questions or medical concerns.
The new VIS is available at www.cdc.gov/vaccines/pubs/vis/default.htm#pcv7. For the latest information concerning VIS updates, visit the CDC's VIS News website. Many VIS forms are available in other languages. As new editions are translated, they are also posted on the Immunization Action Coalition's website.
Updated Recommendation for Use of 7-Valent Pneumococcal Conjugate vaccine
April 7, 2008 -- The Florida Department of Health, Bureau of Immunization announces publication of the Centers for Disease Control and Prevention (CDC), Morbidity and Mortality Weekly Report (MMWR) 2008; volume 57, number 13 on April 4, 2008, concerning 7-valent pneumococcal conjugate vaccine (PCV7). The complete MMWR can be accessed on the web at www.cdc.gov/mmwr/preview/mmwrhtml/mm5713a4.htm
This notice updates the recommendation for use of PCV7 vaccine among children 24 to 59 months of age, who are either unvaccinated or who have a lapse in PCV7 administration. The Advisory Committee on Immunization Practices (ACIP) Pneumococcal Vaccines Work Group reviewed data on PCV7, and on the basis of that review, the ACIP approved the following revised recommendation for use of PCV7 in children 24 to 59 months of age:
- For all healthy children 24 to 59 months of age, who have not completed any recommended schedule for PCV7, administer 1 dose of PCV7.
- For all children with underlying medical conditions, 24 to 59 months of age, who have received 3 doses, administer 1 dose of PCV7.
- For all children with underlying medical conditions, 24 to 59 months of age, who have received less than 3 doses, administer 2 doses of PCV7 at least 8 weeks apart.
No changes were made to previously published recommendations regarding the use of PCV7 in children 24 to 59 months of age; the list of underlying medical or immunocompromising conditions; or the use of 23-valent pneumococcal polysaccharide vaccine in children over 2 years of age, who have previously received PCV7.
The childhood immunization schedule is found at www.cdc.gov/vaccines/recs/schedules/default.htm
